Juno Therapeutics, Inc. — Form D

Juno Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2017-10-05. The offering totals $31.1M, of which $31.1M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (33)

Showing 25 of 33 people.

NameRoleLocation
Hal J BarronDirectorSeattle, WA
HANS BISHOPDirectorMENLO PARK, CA
Thomas Agnes DanielDirectorSeattle, WA
Anthony J EvninDirectorSeattle, WA
Jay J FlatleyDirectorSeattle, WA
Richard J KlausnerDirectorSeattle, WA
Robert J NelsenDirectorSEATTLE, WA
Howard J PienDirectorCorte Madera, CA
Rupert Agnes VesseyDirectorSeattle, WA
Mary Agnes WilderotterDirectorSAN FRANCISCO, CA
Sunil AgarwalExecutive OfficerSeattle, WA
Robert AzelbyExecutive OfficerRedmond, WA
HANS BISHOPExecutive OfficerMENLO PARK, CA
Bernard J CassidyExecutive OfficerSeattle, WA
Steven HarrExecutive OfficerSeattle, WA
HANS BISHOPPromoterMENLO PARK, CA
Richard J KlausnerPromoterSeattle, WA
Robert J NelsenPromoterSEATTLE, WA
Mark FrohlichExecutive OfficerHouston, TX
Mark FrohlichPromoterHouston, TX
Robert NelsenDirectorSeattle, WA
Robert NelsenPromoterSeattle, WA
Richard KlausnerDirectorSouth San Francisco, CA
Richard KlausnerPromoterSouth San Francisco, CA
Howard PienDirectorHarrison, NY

Other filings by this issuer (6)

FiledFormOfferingSold
2017-06-29D/A$898.5M
2016-07-06D/A$896.8M
2015-07-14D$849.8M
2014-08-14D$133.7M$85.5M
2014-05-08D$97.0M$28.4M
2013-12-26D$7.1M$6.7M

More